aTyr Pharma to Present at BIO CEO & Investor Digital Conference
February 09 2021 - 7:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that Sanjay S. Shukla,
M.D., M.S., President and Chief Executive Officer, will present a
corporate overview at the BIO CEO & Investor Digital
Conference, which is being held February 16 – 18, 2021.
The presentation will be available on-demand for
registered attendees of the conference to view. For more
information please visit the Company Presentations section on the
conference website. A replay of the presentation will be available
on the Investor’s section of the company’s website at
www.atyrpharma.com and will be available or 30 days following the
event.
Company management will also participate in
virtual one-on-one meetings during the conference. Meetings can be
scheduled through the conference partnering system or by contacting
investorrelations@atyrpharma.com.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Contact: |
Ashlee Dunston |
Director, Investor Relations and
Corporate Communications |
adunston@atyrpharma.com |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024